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Riska b s t r a c t
Since the mid-1990s, governments and health organizations around the world have adopted policies
designed to increase women’s intake of the B-vitamin ‘folic acid’ before and during the ﬁrst weeks of
pregnancy. Building on initial clinical research in the United Kingdom, folic acid supplementation has
been shown to lower the incidence of neural tube defects (NTDs). Recent debate has focused principally
on the need for mandatory fortiﬁcation of grain products with this vitamin. This article takes a longer
view, tracing the transformation of folic acid from a routine prenatal supplement to reduce the risk of
anaemia to a routine ‘pre-conceptional’ supplement to ‘prevent’ birth defects. Understood in the 1950s
in relation to social problems of poverty and malnutrition, NTDs were by the end of the century more
likely to be attributed to individual failings. This transition was closely associated with a second. Folic
acid supplements were initially prescribed to ‘high-risk’ women who had previously borne a child with
a NTD. By the mid-1990s, they were recommended for all women of childbearing age. The acceptance of
folic acid as a ‘risk-reducing drug’ both relied upon and helped to advance the development of preventive
and clinical practices concerned with women’s health before pregnancy.
 2013 The Author. Published by Elsevier Ltd. All rights reserved.When citing this paper, please use the full journal title Studies in History and Philosophy of Biological and Biomedical Sciences1. Introduction: folic acid and risk reduction
Since the mid-1990s, governments and health organizations
around the world have adopted policies designed to increase wo-
men’s dietary intake of ‘folic acid’ before and during pregnancy
in order to reduce the risk of having a baby with a defect of the
brain and/or spinal cord. Folic acid is the synthetic form of folate,
a B-group vitamin naturally present in many foodstuffs, particu-
larly leafy green vegetables, and presumed essential for cell growth
and development. Neural tube defects (NTDs) such as spina biﬁda
are among the most common congenital malformations and a sig-
niﬁcant cause of neonatal mortality worldwide (Blencowe,
Cousens, Modell, & Lawn, 2010). The proposed link between
dietary folate deﬁciency and birth defects has convinced several
countries to fortify grain products with folic acid (Semba, 2006,
p. 176). Others have relied on health education strategies topersuade women to take a daily supplement of folic acid in order
to ‘help [their] baby develop a healthy brain and body’.1 At least
for those women for whom pregnancy is planned, the decision to
replace the daily ritual of swallowing a contraceptive pill with a vita-
min supplement has come to signify the transition to ‘hoped-for
motherhood’ and a more highly disciplined regime of consumption
(Landsman, 2004, pp. 105–106; Taylor, 2008, p. 127). This article
offers the ﬁrst history of how taking a folic acid supplement became
both a common part of the experience of pregnancy and a drug that
promises to reduce individual risk.
Policies to encourage folic acid consumption are characteristic
of the emphasis on risk prevention that came to dominate the
management of health and disease in developed countries after
1945 (Berridge, 1999; Brandt, 1997; Rothstein, 2003). They are also
a symptom of a broader trend in which the risk to the unborn fetus
has displaced the risk of maternal mortality as the main focus ofuction in
lic-acid-
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2012). Increased emphasis on the management of risk in childbirth
since World War Two has justiﬁed the expansion of obstetric sur-
veillance ever earlier into pregnancy (Arney, 1982, p. 143; Weir,
2006). However, risk prevention strategies have often developed
in piecemeal fashion and cannot be attributed solely to profes-
sional aspirations to extend the scope of obstetric control. Studying
the long-term trajectory of folic acid helps to recover the complex
medical, social and political contingencies that helped to drive this
shift.
Historians have long recognized that ‘risk-reducing’ interven-
tions have not only enhanced the medical scrutiny of subjectively
healthy populations, but also constituted novel categories of pa-
tients and disease states. Commercial promotion, professional
enthusiasm and consumer demand for preventive medical inter-
ventions in chronic conditions such as cancer and diabetes have
blurred the boundary between statistical risk and experienced ill-
ness, creating both symptomless ‘pre-patients’ and treatments for
‘proto-diseases’ (Aronowitz, 2009; Greene, 2007; Löwy, 2010;
Rosenberg, 2007, p. 27; Valier, 2012). In a similar fashion, this arti-
cle suggests, the acceptance of folic acid as a ‘risk-reducing drug’
both relied upon and helped to advance the development of a novel
set of preventive and clinical practices concerned with women’s
health before pregnancy. Originating around 1980, strategies to
promote both ‘pre-conception’ or ‘pre-pregnancy’ care and ‘pre-
conceptional’ vitamin supplementation evolved in close relation
and were mutually reinforcing.
What kind of intervention is pre-conceptional vitamin supple-
mentation? A complete answer would require an international
and cross-disciplinary history over at least the last half-century.
Research on folic acid was—and remains—global and multi-sited;
individual clinical trials could span several countries, as we shall
see. Yet even as the postwar globalization and homogenization of
biomedical knowledge helped constitute folic acid as a risk-reduc-
ing drug, research into this vitamin and strategies to promote its
consumption were also local initiatives, producing local responses.
Expert disagreement over mandatory folic acid fortiﬁcation has
generated considerable international policy controversy over such
issues as individual versus social responsibility, medical surveil-
lance, the effectiveness of health education, and the risk and ben-
eﬁts of population-based interventions with unknown long-term
consequences. This article puts these global debates aside for
now in order to recover the ‘natural history’ of folate deﬁciency
in pregnancy as a health risk.2 Instead, it focuses on the United
Kingdom where much of the important research was done.
A British paediatrician, Richard Smithells, is credited with sug-
gesting the ‘causal’ link between folate deﬁciency and NTDs, which
a multi-centre clinical trial conducted by the UK Medical Research
Council (MRC) is typically claimed to have conﬁrmed. First tracing
the history of folic acid in Britain, I propose that two factors signif-
icantly shaped this research and its local reception: one, the long-
standing and widespread acceptance of vitamins, including folic
acid, as beneﬁcial to pregnant women; two, the rise to political
prominence of spina biﬁda, the most common NTD, from the
late-1960s. The second half of the article analyses the controversy
around the MRC clinical trial and its immediate aftermath. This fo-
cus illuminates the multiple constituencies involved in the co-con-
struction of folic acid as a risk-reducing drug and pre-conception
care. I suggest that the controversy mobilized a heterogeneous
set of actors—research scientists, clinicians, food and drugs compa-
nies, activists and journalists—with different interpretations of risk2 Robert Aronowitz has called for greater historical sensitivity to the ‘‘generation-speci
prevention practices’’ (2006, p. 156).
3 Quotations from advertisements for Stork and Bemax in the Observer, 24 April 1938:and uncertainty to claim a stake in pre-conceptional vitamin sup-
plements as a means of preventing NTDs.
2. From Marmite to folic acid: vitamin supplements in
pregnancy
Dietary prescriptions had long been a staple of informal health
guidance to expectant and nursing mothers before rising concern
about infant mortality around 1900 consolidated the status of
nutritional advice in voluntary and statutory systems of maternal
and child welfare (Cody, 2011; Dwork, 1987; Oakley, 1984). In
the following decades, pregnant women were identiﬁed as impor-
tant beneﬁciaries of the new knowledge of vitamins, deployed by
not only medical practitioners and public health workers, but also
charitable, educational and campaigning organizations. Manufac-
turers of ‘nutrient-rich’ proprietary foods such as Marmite, made
from yeast extract, Stork margarine and the stabilized wheatgerm
Bemax stressed that ‘vitamin need’ was ‘especially important in
the case of the expectant mother, as any Maternity or Child Wel-
fare centre will conﬁrm’. The marketing of vitamin supplements
as ‘indispensible’ for pregnant women, ‘for their own sake and that
of the child’, extended a long tradition of emphasizing family nutri-
tion as mothers’ responsibility and duty (Apple, 1995; 1996, p.
182).3
Many interwar health workers were convinced of the value of
Marmite and other vitamin-rich preparations in reducing the risk
of death in childbirth. By distributing Marmite and other supple-
ments to working-class expectant mothers in England and Wales,
the voluntary National Birthday Trust Fund and the People’s Lea-
gue of Health could combine relief with research into the impact
of prenatal nutrition on maternal mortality (People’s League of
Health, 1946; Williams, 1997). This conviction informed ofﬁcial
wartime nutrition policies. The supply of free or cheap vitamin A
and D tablets, milk, orange juice and cod liver oil to expectant
mothers and children through the wartime vitamin welfare
scheme, with their perceived role in the decline of maternal mor-
tality, consolidated the importance of dietary supplements in preg-
nancy. At the war’s end, the Ministry of Food could declare that the
national provision of milk and vitamin supplements to these ‘prior-
ity groups has probably done more than any other single factor to
promote the health of expectant mothers and young children’
(quoted in Oakley, 1984, pp. 124–125; Sultan, 2010; Zweiniger-
Bargielowska, 2000, pp. 130–134).
Like for other vitamins and vitamin products, the relations be-
tween medical researchers, philanthropists, industry and pregnant
women in the 1930s helped constitute the therapeutic identity of
folic acid (Kamminga, 1998). Working in India in the 1930s, the
British pathologist Lucy Wills described a severe and often fatal
anaemia associated with pregnancy that was especially prevalent
among undernourished urban textile workers. The symptoms of
‘tropical macrocytic anaemia’ closely resembled those of perni-
cious anaemia, established by 1934 as a disease curable by liver ex-
tract (Wailoo, 1999, pp. 99–133). In research funded by the Lady
Tata Memorial trust, founded by the Indian businessman Dorabji
Tata in 1932, Wills and her collaborators studied the effects of die-
tary manipulation in albino rats, rhesus monkeys and hospital pa-
tients in Bombay and later in London. She observed that
macrocytic anaemia could be treated effectively with both crude li-
ver and yeast extract supplied by the Marmite Food Extract Com-
pany. This ﬁnding both differentiated the disease from pernicious
anaemia and demonstrated the presence of a previously unknownﬁc and contingent inﬂuences on the appearance and identity of risks, diagnoses and
28 and the Guardian, 7 May 1953, p. 4.
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1933; Wills & Evans, 1938). The so-called ‘Wills factor’ of yeast ex-
tract and crude liver was later identiﬁed as a family of compounds
that biochemists in Texas ﬁrst isolated in 1941 by concentrating
four tons of the spinach that gave folic acid its name (folium = leaf
[Lat.]) (Mitchell, Snell, & Williams, 1941). Synthesized by chemists
at the American pharmaceutical company Lederle in 1945, folic
(also pteroylglutamic) acid quickly became a tool of clinical medi-
cine and research (Hoffbrand & Weir, 2001).
Lederle’s ‘new yellow vitamin’ that ‘builds red blood cells’ and
‘helps anemic expectant mothers’ was one of many new technolo-
gies taken by haematologists to embody the promise of biochemi-
cal blood manipulation and analysis in the postwar era (Lederle,
1950).4 As Keith Wailoo has argued for liver extract in pernicious
anaemia, the identities of folic acid and macrocytic (and later ‘meg-
aloblastic’) anaemia, conditions particularly prevalent among preg-
nant women, were mutually constitutive. Understanding of these
diseases depended upon not only the collaboration of clinicians
and academic researchers, but also ‘the manufacturing, packaging,
advertising, and promotion of the cure’ (Wailoo, 1999, p. 132). Post-
war haematologists investigated the role of folate activity in the
anaemias, especially in conjunction with vitamin B12, isolated from
liver in the late-1940s. By around 1960, researchers had developed
several techniques for diagnosing folate deﬁciency, including bio-
chemical tests and animal and microbiological assays of blood ser-
um, each of varying degrees of sensitivity and speciﬁcity.
One such method involved testing urine for abnormally high
levels of ‘formiminoglutamic acid’ (FIGlu), an intermediate in the
metabolic breakdown of the amino acid histidine, for which folate
was understood to be integral. So by giving anaemic patients a
large oral dose of histidine, increased FIGlu excretion offered a bio-
chemical index for the diagnosis of clinical folate deﬁciency (Luh-
by, Cooperman, & Teller, 1959). Although the test was complex
and proved difﬁcult to interpret, high-voltage electrophoresis
‘greatly simpliﬁed’ the FIGlu assay (Hibbard, 1964; Metz, 1963, p.
526). Like other methods of blood analysis in this period, diagnos-
tic tests for folate deﬁciency migrated beyond the expert province
of haematology into other clinical disciplines (Wailoo, 1999, pp.
154–157, 162–187). Biochemical tools offered obstetricians and
paediatricians, in particular, new ways of thinking about
pregnancy.
By the mid-1960s, extensive clinical studies of the megaloblas-
tic anaemias of pregnancy using such techniques brought into view
a previously unknown problem: most pregnant women had mild
folate deﬁciency whilst showing no signs of clinical disorder. Be-
cause of the now acknowledged role of folic acid in metabolism
and cell growth, haematologists and obstetricians surmised that
the developing fetus raised the physiological demand for the vita-
min (Chanarin, Rothman, & Berry, 1965). Even otherwise healthy
pregnant women needed supplementary folate to restore their re-
serves of the vitamin to ‘normal’ levels. In the postwar period,
megaloblastic anaemias were common in ‘peoples with low stan-
dards of living in tropical and sub-tropical areas’, but rare in ‘devel-
oped’ countries like the UK. Metabolic studies of folate activity lent
weight to the view that pregnant women were, in haematological
terms, akin to the poorly nourished populations in the ‘underdevel-
oped’ world most vulnerable to this condition (Anon, 1964b,
1968b).
The fact that sub-clinical folate deﬁciency put pregnant women
at ‘unnecessary risk’ of overt megaloblastic anaemia, moreover,
justiﬁed the ‘ritual’ prescription of folic acid and iron supplements
to expectant mothers at British antenatal clinics by the late 1960s4 ‘The ﬁrst pinch cost a fortune’, Advertisement for Lederle, Life, 17 November 1952, p.
5 See advertisement for Marmite Yeast Extract, in the Journal of Tropical Pediatrics 13, 1(Anon, 1966; Today’s Drugs, 1967). Yet even as prenatal folic acid
supplementation became ever more routine, some medical practi-
tioners challenged the efﬁcacy of a ‘technological ﬁx’ to a condition
that manifested clinically in only relatively few pregnant women.
One clinician protested that this ‘blanket prescribing policy’ was
not only expensive and ineffective (since many women did not
take the supplements), but diverted attention from ‘the real prob-
lem’: improving nutritional education and inﬂuencing national
policies so that the population as a whole was ‘more likely to eat
a nutritionally sound diet’ (Smail, 1981).
Research into megaloblastic anaemia and pregnancy neverthe-
less stimulated medical interest in the wider role of folate metab-
olism in reproduction. Obstetricians looked beyond maternal
anaemia to focus on the clinical manifestations of folate deﬁciency
in the fetus and newborn, including abortion, prematurity and con-
genital malformations (Hibbard & Hibbard, 1968). By studying
‘tropical’ populations with diets known to be low in uncooked
green vegetables, clinical researchers could increasingly claim fo-
late deﬁciency as a cause of ‘reproductive wastage’ (Baumslag,
Edelstein, & Metz, 1970). Such observations built on awareness
that the folate antagonist aminopterin, a drug used to treat child-
hood leukaemia, was also an abortifacient (Anon, 1977; Thiersch,
1952), as well as a body of experimental research linking develop-
mental abnormalities with vitamin-deﬁcient diets. By starving
pregnant laboratory animals of B-group vitamins riboﬂavin, panto-
thenic acid and folic acid, several teratologists had by around 1950
successfully produced ‘deformities . . .encountered as congenital
malformations in man’ (Woollam & Millen, 1956, p. 1264).
Promoted since the 1930s as ideal nourishment for pregnant
women, B-vitamin-rich yeast extract was in the 1960s claimed as
beneﬁcial for the developing fetus as well. The manufacturers of
Marmite targeted medical practitioners in the developing world
by advertising in the Journal of Tropical Pediatrics: babies, they
claimed, needed ‘Marmite before birth’.5 While medical interest
was by then directed at one of yeast extract’s molecular components,
chemically synthesized folic acid, the rebranding of Marmite is a re-
minder of the multiple connections between the food industry, clini-
cians, academic scientists and consumers that have given vitamins
and vitamin preparations in general such importance to medical
and lay perceptions of health and disease since the early twentieth
century. The postwar therapeutic identity of folic acid depended,
in particular, on the longstanding emphasis on expectant mothers
as especially appropriate consumers of vitamin supplements.
Through new biochemical technologies, folic acid in turn forced
obstetricians to revise their understanding of metabolism in preg-
nancy. This conjunction would, in the early 1980s, transform both
folic acid and pregnancy once again.
3. Monitoring, treating and preventing NTDs after thalidomide
Revelations in the early 1960s that the anti-nausea drug thalid-
omide had caused birth deformities on a huge scale, prompted
widespread discussion about the permissibility of abortion across
Western Europe and North America. Although the movement for
abortion law reform can be traced at least as far back as the
1930s, recent historical writing has stressed that the thalidomide
disaster, together with publicity given to fetal abnormalities
caused by rubella during global epidemics of 1962–1964, provided
a major impetus to the liberalization of abortion (Parker, 2012;
Reagan, 2010). The concurrence of abortion legalization and the
development as diagnostic tools of chromosome analysis, amnio-
centesis, screening for serum markers and obstetric ultrasound72.
967, frontmatter.
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natal testing into clinical routine in the 1970s. With prenatal diag-
nosis as its ‘technological handmaiden’, genetic counselling
developed into a practice for deﬁning and handling the various
risks associated with the birth of a handicapped child (Gaudillière,
2011; Stern, 2012, p. 168).
While postwar transformations in medical genetics are well
documented, historians have yet fully to recognize parallel con-
cerns about the environmental causes of birth defects. Although
clinical observations and experimental studies of environmental
factors in development proliferated before World War Two, British
epidemiological interest in congenital malformations originated
largely in the postwar reconstructive ideals of social medicine
(Porter, 1997). Dugald Baird, director of the Aberdeen Social
Obstetric Unit led a range of studies indicating that high fetal mor-
tality correlated with poor social conditions (Davis, 2009). Baird
and his colleagues argued that eliminating poverty and improving
women’s health and nutrition during growth and adolescence as
well as pregnancy would lower the incidence of stillbirths (Baird,
1974; Duncan, Baird, & Thomson, 1952). Declining mortality from
infectious disease made congenital malformations more visible as
causes of stillbirth and infant and childhood mortality. Thomas
McKeown and collaborators at the Department of Social Medicine,
University of Birmingham, explored environmental inﬂuences such
as season of birth, maternal age and birth rank and showed how
these were related to socio-economic status (McKeown & Record,
1951; Record & McKeown, 1949).
This work initiated the ﬁrst population-based continuous regis-
ter of malformations, which stimulated an international network
of similar registers (Leck, 1996). Attention to the surveillance of
birth defects had intensiﬁed enormously in Britain during the
1960s in response to thalidomide and epidemics of German mea-
sles. In 1964 the Ministry of Health instituted a formal system of
registering congenital malformations, with the aim of establishing
typical seasonal and regional variations in incidence, and of warn-
ing quickly of any unusual increases (Anon, 1964a, pp. 71–72).
These registries revealed especially high rates of NTDs in particular
regions of Britain: north-west England, Northern Ireland and the
coal-mining valleys of South Wales. Much subsequent research
was predicated on the assumption that the prevalence of NTD
births was highest in the ‘underprivileged areas of poverty’ (Nevin,
2004; Stocks, 1970). In some regions, incidence was as high as four
in every 1000 births (Anon, 1968a).
British epidemiologists’ preoccupation with NTDs developed in
tandem with intense public concern about the medical, social and
ethical dilemmas associated with innovations in the surgical treat-
ment of spina biﬁda. Before 1960, the survival rate for all forms of
spina biﬁda was 10% to 12%. Paediatric surgeons typically post-
poned treatment until the infant reached the age of two, believing
that only the strongest would survive that long. However, many
surgeons increasingly argued that early intervention signiﬁcantly
improved the prognosis of spina biﬁda babies. Supported by the
increasingly widespread provision of specialist neonatal care
(Christie & Tansey, 2001; McAdams, 2008), most paediatric units
in the UK by the mid-1960s operated within 12 to 48 hours of birth
on all infants who did not have other defects incompatible with life
(Pruitt, 2012; Sharrard, Zachary, & Lorber, 1967). Although this shift
in practice requires further historical analysis, contemporaries per-
ceived a ‘spectacular increase in the number of newborns [with spi-
na biﬁda] admitted to the few centres in Great Britain which are
equipped to deal with them’ (Anon, 1964c). By the mid-1960s,
NTDs had become an ‘urgent medical, social, epidemiological, and6 This debate was crucial to arguments that external oversight would make medicine mo
1970s: Wilson (2012).aetiological problem’ (Laurence, Carter, & David, 1968). Two new
charities, the Association for Spina Biﬁda and Hydrocephalus (AS-
BAH) and the Spina Biﬁda Trust, responded to mounting concern
by fundraising for medical research and to support families and
individuals affected by these conditions. Action Research for the
Crippled Child (ARCC), one of the major charities supporting med-
ical research in the UK, also shifted its funding priorities from polio
to congenital malformations in the mid-1960s (Action Medical Re-
search, 2012).
The increased visibility of spina biﬁda in the 1960s precipi-
tated discussions about the ‘burden’ of the physically handi-
capped on not only individual families, but also the public
purse. Even as disability rights activists began to campaign for
better access to education and employment (Millar, 2010), many
commentators worried about the greater demands of ‘long-term
survivors’ of spina biﬁda for specialist medical care and schooling.
According to Gerald Leach, science correspondent for the Observer
newspaper, resource allocation to cope with the ‘rising tide of
chronic handicap’ urgently needed debate (1970, p. 182). For
McKeown, because the ‘malformed child’ represented an ‘intoler-
able burden on the medical and social services’, it was time to
‘establish national priorities in the use of medical manpower’
(1967, pp. 1223–1224). Other medical practitioners more
bluntly—and provocatively—argued that ‘the spina biﬁda baby is
a mistake of nature not equipped to survive . . . the death costs
nothing; the life costs not only money but the pre-emption of
precious medical, nursing, social and educational resources’ (Sla-
ter, 1971, p. 735). Although many paediatricians began to endorse
the view that ‘society needed to take a more selective approach’
to early surgical intervention (Anon, 1972), the alleged ‘neonatal
euthanasia’ of spina biﬁda babies had become increasingly con-
troversial (Anon, 1974).6
New emphasis on the ‘prevention of handicap’ as a solution to
these social and ethical dilemmas during the 1970s was part of a
broader trend in public health in Britain. The policy focus on ‘pre-
vention’ as a matter of personal responsibility originated in the
postwar period as epidemiological attention shifted from infec-
tious to chronic diseases as the major cause of ill health and mor-
tality. But the notion of prevention as individual responsibility was
carried further in the 1970s, especially following the inﬂuential
1976 Department of Health and Social Security policy report, Pre-
vention and Health: Everybody’s Business (Berridge, 1999, pp. 87–
88; DHSS, 1976). Prevention and Health, Reducing the Risk: Safer
Pregnancy and Childbirth (DHSS, 1977), the ﬁrst of a series of fol-
low-up discussion papers, sought to determine how far the new
philosophy of preventive medicine could be applied to pregnancy
and childbirth. Of particular concern was the need to reduce the
prevalence of handicap, claimed to impose ‘great burdens on our
society’. Because of the ‘substantial costs’ of treating spina biﬁda
in particular, a programme to prevent the birth of children with
this disability promised almost immediate savings (DHSS, 1977,
pp. 7, 42, 48). In practice, this meant supporting the extension of
new prenatal diagnostic technologies into comprehensive screen-
ing, and offering women the choice to terminate an abnormal preg-
nancy. Research in the 1970s led by the Edinburgh geneticist David
Brock established that elevated levels of alpha-fetoprotein (AFP) in
amniotic ﬂuid and later, in pregnant women’s blood indicated that
the fetus was at risk of NTD led rapidly to routine testing for this
marker (Brock & Hughes-Davis, 1974; Brock & Sutcliffe, 1972).
The cost-beneﬁt rationale remained omnipresent in discussions
around the introduction of these technologies as medical care
was increasingly constrained by budgetary pressures in there accountable to the public, and in the emergence of bioethics in Britain from the late
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164).
However, the rapid diffusion of amniocentesis and AFP-
screening in the late-1970s was not uncontested, and ‘preven-
tion’ did not only mean abortion. The Royal College of Obstetri-
cians and Gynaecologists initially resisted the generalizing of
prenatal screening on the grounds that the technology was
not foolproof; members feared the prospect of terminating
healthy pregnancies following false positives (Yanchinski,
1978). Other clinicians worried that health service planners’
use of prenatal diagnosis and selective termination was over-
shadowing ‘research into the causes and true prevention of birth
defects’ (Harris, 1980, p. 1199). This included studies into the
teratogenic properties of new drugs, infectious diseases, syn-
thetic hormones, environmental pollutants, alcohol and smoking.
In the period after thalidomide, the popular and medical press
frequently reported new theories about the alleged causes of fe-
tal deformities (Renwick, 1972, p. 279). As an editorial in the
New Scientist observed, ‘the thalidomide tragedy . . .transformed
teratology from an obscure laboratory game into a valuable clin-
ical science’ (Anon, 1973). While many theories were discounted
as quickly as they were proposed, the possibility that vitamin
deﬁciencies increased the risk of NTDs remained persuasive.
In the 1960s, the paediatrician Richard Smithells collaborated
with local obstetricians in researching folate metabolism in repro-
duction in Liverpool, noted for its high NTD prevalence. Smithells
had set up a congenital abnormalities register and genetic coun-
selling service for Liverpool in 1960 (Smithells, 1962) and became
the leading British expert on thalidomide diagnostics. Offering
medical testimony to support the plaintiffs’ case against the
drug’s UK distributor, he was subsequently involved with the
trust set up to provide ‘relief and assistance’ to thalidomide chil-
dren (Schorah, 2009). Smithells then started a series of small-
scale studies that suggested a ‘signiﬁcant relationship’ between
a positive FIGlu test for folate deﬁciency and fetal malformation
(Hibbard & Smithells, 1965). With funding from the ARCC and
the Children’s Research Fund, a Lancashire-based charity estab-
lished in the wake of thalidomide, Smithells built a research
group at the University of Leeds to investigate the broader role
of drugs and nutrition in pregnancy and birth defects (Smithells,
Sheppard, & Schorah, 1976; Smithells et al., 1977). Motivated by
the view that the diagnosis and termination of a fetus with spina
biﬁda was a ‘poor substitute for prevention’ (Anon, 1992, p.
1062), Smithells proposed to subject the folate hypothesis to
the scrutiny of a clinical trial. What if a woman ‘at risk’ of having
a child with an NTD could be given supplementary vitamins be-
fore her next pregnancy? Thalidomide had revealed that drugs
could harm the developing fetus, but could a pharmaceutical
product be shown to prevent birth defects?
Such an experiment was plausible only in a British medical and
social landscape transformed by thalidomide and the legalization
of abortion. The rapid expansion of prenatal diagnosis in the ten
years after the Abortion Act consolidated the genetic counselling
clinics from which women with a history of an NTD pregnancy
could be recruited. Yet the possibility of a trial relied upon not only
the willingness of what the tabloid press came to call ‘heartbreak
mums’ to be recruited, but also the construction of spina biﬁda
as an ‘urgent’ problem for the medical profession, charities and
society at large. Launching a clinical trial in 1977, Smithells would
transform folic acid from a routine prenatal vitamin to reduce the
risk of anaemia into an experimental drug for preventing NTDs in
‘high-risk mothers’.7 Lancet, 22 March 1980, pp. 647–648; 17 May 1980, pp. 1061–1062; 14 June 1980, p.
8 Clinicians and epidemiologists were similarly divided over the relationship between l4. Trialing pre-conceptional vitamin supplements and
‘high-risk mothers’
Smithells’ team at Leeds, with collaborators in Manchester,
Chester and London, succeeded in recruiting 137 ‘study mothers’
into a trial of ‘Pregnavite Forte F’, a multivitamin containing folic
acid manufactured by the British pharmaceutical company Bee-
cham and available only on prescription. Each woman agreed to
take three tablets a day for no fewer than 28 days before concep-
tion, up until the date of the second missed period. A second group
of 187 women who were already pregnant when referred to the
study or who declined to take supplements were used as controls.
The preliminary ﬁndings, published in the Lancet in 1980, sug-
gested that the NTD recurrence rate in supplemented mothers
was around half that of the control group (Smithells et al., 1980).
Smithells framed this research as contributing to the ‘primary pre-
vention’ of malformations, as opposed to ‘secondary prevention’
through prenatal screening. The promise of reducing not only birth
incidence of neural-tube defects but also the need for selective ter-
minationmade this an ‘exciting ﬁnding’ in the context of continued
debate over abortion (Anon, 1980; Davis, 1985).
In the weeks and months following its publication, Smithells’
report attracted a lively correspondence in the Lancet. Critics
rounded on the design of the trial; in particular, the ‘self-selecting’
method of recruiting participants and the use of a ‘blunderbuss’
multivitamin. Smithells and his colleagues were accused of induc-
ing women to ‘self-administer large quantities of multivitamins’ on
the basis of a trial that was not properly controlled, and failing to
resolve uncertainty over the causal relationship between folic acid
and NTDs.7 Despite these doubts, the practical response of many cli-
nicians was to behave as if there was a link. Within months, genetic
counsellors were ‘already recommending [Pregnavite] to mothers
with a history of NTD pregnancies’ (MRC ﬁle note, National Archives
FD23/5150). Many clinicians were prepared to accept Smithells’ re-
sults as imperfect, but adequate in practical terms. For epidemiolo-
gists, however, the design of the trial could not support valid
conclusions of cause and effect and—potentially worse—generated
new risks over the actions of vitamins that were ‘imperfectly
understood’.8
Long-term prenatal multivitamin supplementation raised the
spectre of the synthetic estrogen diethylstilbestrol (DES), recently
found to have caused genital malformations and cervical cancer
in the daughters of pregnant women to whom it was prescribed
to prevent miscarriage (Chalmers & Sacks, 1982; Langston, 2010).
To Smithells’ critics, the poorly designed trial rendered Pregnavite
‘of such uncertain efﬁcacy and safety that it should be regarded as
a subject of clinical research rather than accepted medical practice’
(MRC press release, National Archives FD23/5152). While acknowl-
edging the need for more research, Smithells and his supporters
employed the language of ‘promise’ and ‘guarded optimism’
(MRC ﬁle, National Archives FD23/5150). Those for whom a dou-
ble-blind, placebo-controlled trial was the bottom line spoke of
continued ‘uncertainty’ and new ‘risks’. Even as medical practitio-
ners prescribed vitamins to high-risk mothers, the debate over the
credibility of existing data intensiﬁed. The decision of the Medical
Research Council, at the request of the UK government, to initiate a
randomized controlled trial of pre-conceptional vitamin supple-
mentation marked the start of a more public phase in what was la-
ter claimed as ‘one of the great medical controversies of the
twentieth century’ (Stone, 1991).
The randomized clinical trial (RCT) had, by around 1970, gained
a form of scientiﬁc and bureaucratic orthodoxy as the ‘gold1302.
ow-level radiation and childhood leukaemia in the 1950s: Dry (2006).
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Marks, 2003; Löwy, 1996, pp. 36–83; Marks, 1997). The epistemo-
logical success of the multi-centre RCT in Britain was largely the
achievement of the MRC, whose pioneering trials of the anti-tuber-
culosis drug streptomycin in the late 1940s laid the parameters for
biomedical research during a period of increased centralization of
health policy and planning. Supporting the new role of the state
as ‘scientiﬁc entrepreneur’, the MRC pursued RCTs as ‘a means of
unifying a research landscape that was characterized by localism’
(Valier & Timmerman, 2008, p. 494). Research into the role of folate
deﬁciency in reproduction had certainly been located in heteroge-
neous disciplinary traditions that served various academic, clinical,
and charitable agendas. The suggestion that pre-conceptional vita-
mins could reduce NTD prevalence by half now had such signiﬁ-
cant health policy implications as to push the MRC to become
involved. Should the state fund the provision of folic acid supple-
ments, or a proprietary multivitamin at more than 35 times the
cost?9 How, above all, to reach women before they became preg-
nant? Ofﬁcial recognition of the need for a multi-centre RCT not only
reﬂected the view that previous studies, with their diverse sources of
funding and research protocols, were too inconclusive to inform
such major policy decisions as the national healthcare budget con-
tracted under the Conservative government of Margaret Thatcher.
It also reinforced the position of the MRC as the pre-eminent pro-
ducer of medical knowledge and arbiter of best practice in the UK.
Yet even as the MRC and other organizations consolidated the
status of the RCT, controversies over human experimentation
through the late 1960s and 1970s began to change the landscape
of clinical research (Cooter, 2000, pp. 458–459). In response to
mounting critiques of risky clinical experimentation without in-
formed consent, British hospitals set up speciﬁc committees to
oversee the ethics of medical research. In 1984, one year into the
MRC vitamin study, the Department of Health established Local Re-
search Ethics Committees with the aim of enhancing protections
for subjects based on the principles of the Helsinki Declaration of
1964 of the World Medical Association (WMA) (Hazelgrove,
2002; Hedgecoe, 2009). Amendments to the Helsinki code at the
WMA assembly in 1975, the ﬁrst of eight subsequent revisions to
date, placed particular emphasis on tightening deﬁnitions of in-
formed consent (Faulder, 1985, pp. 48–49). MRC policy on in-
formed consent in the 1980s had been laid down in a 1964
statement on ‘Responsibility in Investigations on Human Subjects’,
long regarded as the authoritative guide for clinical research in the
UK. This distinguished between procedures of ‘beneﬁt to the indi-
vidual’ and those ‘undertaken either on patients or on healthy sub-
jects solely for the purpose of contributing to medical knowledge’.
Investigators were required to obtain ‘explicit’ written consent in
the latter case but not the former, since experimental treatments
were assumed to ‘fall within the ambit of patient-care’ (MRC,
1964, p. 178).
Through the 1980s and 1990s, new procedures for the oversight
of the profession emerged alongside rising appeals for lay involve-
ment in the administration of clinical research in the form of pa-
tient activists and advocates, consumer groups and the
independent discipline of bioethics (Dawes, 2012; Epstein, 1996;
Wilson, 2012). By the 1970s the mass media was becoming ever
more central to establishing the dimensions of scientiﬁc and med-
ical controversies, including shaping both lay and professional per-
ceptions of certainty, uncertainty and ethical practice in clinical
trials (Berridge & Loughlin, 2005; Epstein, 1996, p. 22). The MRC
trial launched just as the long-running public controversy over
claims that large doses of vitamin C could cure cancer was about9 In 1991, a year’s supply of folic acid supplements cost £1.24 per person, compared wi
10 Multivitamins and neural tube defects: draft minutes of an ad hoc meeting, 15 Decem
11 Letter from Daily Mail medical correspondent Paul Crosbie to Sir James Gowans, secreto reach its climax (Richards, 1991). Meanwhile, tighter regulation
of drugs testing in both the UK and the US, along with increasing
demands for larger trials to ensure greater statistical conﬁdence
in the results encouraged the ‘outsourcing’ of clinical research,
especially to middle- and low-income countries from the 1980s
(Petryna, 2009). Symptoms of all these trends can be seen in the
design of and response to the MRC vitamin study.
The MRC steering committee established to design and coordi-
nate the trial ﬁrst convened in February 1981. The study was ﬁnal-
ly launched late in 1983, initially involving 17 participating centres
in the UK (MRC Vitamin Study Research Group, 1991). From the
outset the MRC was sensitive to the ethical implications of enroll-
ing women who had previously had an NTD baby and were plan-
ning another pregnancy into a controlled trial. This would mean
randomly allocating subjects into one of three control groups:
the ﬁrst to take a daily Pregnavite multivitamin, the second a 5-
milligram dose of folic acid, and the third a placebo. Where manda-
tory AFP testing and amniocentesis indicated a fetal NTD, women
would be offered an abortion. The steering committee initially
spoke of recruiting a minimum of 2000 and as many as 5000 par-
ticipants over three years, but asserted that the trial would be ter-
minated as soon as there was statistically signiﬁcant evidence of a
‘very marked’ reduction in NTDs in either arm of the study (Na-
tional Archives, MRC press release; Report to the Systems Board
FD23/5152). Criticisms of the proposals surfaced immediately,
with some experts invited to comment on the trial design arguing
that it would be ‘unacceptable to withhold a harmless, and possi-
bly beneﬁcial, treatment fromwomenwho had presented for treat-
ment.’10 John Davis, the Cambridge professor of paediatrics
appointed to chair the MRC study group, was soon ‘bombarded’ with
letters from medical colleagues critical of plans to include a placebo
group (Davis, 1982d).
The debate spilled into public view early in 1982 as journalists
picked up on expert disagreement over the feasibility and ethics of
a placebo-controlled trial. The Oxford geneticist John Edwards’
proclamation on BBC television’s ﬂagship science programme
‘Tomorrow’s World’ that the MRC trial was unethical sparked a
‘media storm’ that would delay the launch of the trial by over a
year (Edwards, 1982a, 1982b). The lay press were universally hos-
tile to the trial, presenting Smithells’ ‘remarkable’ ﬁndings as hav-
ing settled the issue (King, 1982). Newspaper copy denounced the
MRC for ‘deceiving’ thousands of women into what amounted to a
‘cruel game of Russian Roulette’ (Toulson, 1982). The steering com-
mittee sought to manage the controversy by warning editors in
both the lay and scientiﬁc press that ‘public and emotive deba-
te . . . [made] better journalism rather than better medicine’ (Davis,
1982b). But the debate had already moved far beyond their control
even when an opposition politician demanded the MRC abandon a
‘miserable and unworthy piece of medical research’ (Medical Cor-
respondent, 1982). By December 1982, public controversy over the
placebo left the MRC with a ‘debacle’ that threatened the likelihood
of recruiting sufﬁcient numbers of research subjects (Davis, 1982c;
Middlemiss, 1983).
That the media should, from the point of view of the MRC, ‘triv-
ialise’ scientiﬁc debate over the conclusiveness of Smithells’ results
and the necessity of a placebo, is not surprising.11 Yet the MRC had
little, if any, previous experience defending the design of a clinical
trial in public. The pre-conceptional vitamin study set a precedent
for well-known controversies over placebo-controlled trials of the
AIDS drug AZT later in the 1980s (Berridge, 1996, p. 235; Campbell,
1988; Epstein, 1996). The major consequence of journalists’ atten-
tion was that it hardened many experts’ private concerns aboutth £44 for the Pregnavite Forte F multivitamin: Kingsland (1991).
ber 1980 (National Archives, FD23/5150).
tary of the MRC, 9 December 1982 (National Archives, FD23/5154).
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put it, ‘now that [Smithells’ evidence] has been accepted by ‘Tomor-
row’s World’ any criticism must be clear and open’ (Edwards,
1982b).
As for Smithells’ results, disciplinary factors played a central
role in dictating positions for and against the trial. Epidemiologists
defended the placebo-controlled trial as a ‘social responsibility’
and the only way to achieve scientiﬁc certainty (Doll, 1982). The
organizers argued that participants in the trial would be willing
to ‘pay the price’ of an abortion ‘in order to contribute certain
knowledge where at the moment only opinion prevails’ (Davis,
1982a). The most stringent opposition came from clinicians con-
cerned that they could not subject women to the risk of a placebo
without violating ordinary responsibilities of patient care, not least
because vitamins, including folic acid, were already so widely rec-
ommended in pregnancy. Doctors critical of the trial typically in-
voked personal moral judgment, advising patients that that they
‘would not wish a member of [their] own family to forgo the pos-
sible advantages of supplementation’ (Davis, 1981). Disagreement
hinged above all on whether women recruited to the trial should
be considered pure research subjects or patients, a distinction that
would in turn determine the necessity of obtaining explicit in-
formed consent (Davis, 1982c). Lack of clarity on this issue pro-
voked concern that doctors who participated in the study could
be liable to charges of negligence (Leahy Taylor, 1983).12 In sum,
even as the inclusion of a placebo group promised to give the MRC
study the biomedical credibility that Smithells’ research lacked, it
threatened to undermine the credibility of medicine as a healing
profession (Faulder, 1985, pp. 92–93). The controversy pitted what
one opponent of the MRC trial termed ‘common sense against the
purism of some academic epidemiologists’ (Renwick, 1982).
A year into the MRC study, participating centres had managed
to recruit a total of just 132 women, far short of the minimum
2000 target (Abel, 1984). When the trial was ultimately concluded
it was widely assumed that the ‘media storm’ of the early 1980s
‘slowed recruitment to such an extent that it took eight years to
accumulate enough participating women and enough pregnancies’
for a ‘conclusive’ result. Although the possibility of recruiting sub-
jects from outside Britain had been mooted from the start, the
study ultimately relied upon 16 centres in Australia, France, Israel,
Hungary and the then USSR. More volunteers were enrolled at the
seven centres in Hungary than the UK, despite a similar NTD rate
(Anon., 1991, p. 153). Public controversy around the ethics of the
trial forced those with a stake in the research into polarized posi-
tions on the reliability and implications of Smithells’ ﬁndings: as
being either for ‘social responsibility’ or opposed to ‘denying’
‘high-risk mothers’ and their fetuses the vitamin supplements they
required. The extension of the debate beyond the medical press not
only raised the stakes for the researchers, but also brought a range
of new participants’ differing perceptions of risk, nutrition, moth-
erhood and disability into conﬂict.
5. Constructing pre-conceptional nutrition
The MRC vitamin study group announced the results of the trial
in 1991, claiming a ‘72% protective effect’ for folic acid in at-risk
pregnancies (MRC Vitamin Study Research Group, 1991). An edito-
rial in the Lancet declared the debate over the connection between
folate deﬁciency and NTDs ‘resolved at last’, while promoters of
‘evidence based medicine’ would commend the study as a model12 This distinction had led the MRC, a decade earlier, to reject an application for support
13 Nature, 25 November 1982, p. 302.
14 See Kellogg advertisement for fortiﬁed cornﬂakes in The Guardian, 18 December 1991
15 The anthropologist Janelle Taylor has suggested that the use of fetal images in advertisin
(2008, p. 3).of good practice (Anon, 1991; Oakley, 1990; Chalmers et al.,
1993). Such acclaim both disguised earlier disagreement and failed
to anticipate new debate over the implications of the study’s ﬁnd-
ings. Above all, 95% of NTDs were ﬁrst-occurrence; the question re-
mained as to whether folic acid supplements would ‘protect’
women with no previous history of an NTD pregnancy (Czeizel &
Dudás, 1992). Moreover, claims that the statistical rigour of the
trial produced deﬁnitive answers overlooked the vital role of
groups other than MRC epidemiologists in tipping the balance of
certainty and uncertainty. The new identity of folic acid as a risk-
reducing drug depended on the agency of non-experts.
First, the media, as discussed above, played a major part in the
controversy, not merely communicating expert disagreement, but
also shaping both professional and lay perceptions of risk and
uncertainty. Mass media debate required that protagonists adopt
a clear position on the ‘ethics’ of the trial and, thus, the efﬁcacy
of pre-conceptional vitamins in reducing the risk of NTDs. Medical
researchers and practitioners used the media to declare their sup-
port or opposition to the trial and journalists intervened directly,
too. The feminist health rights activist and journalist Carolyn Faul-
der, for instance, framed the trial as part of a patient-consumer
struggle for informed consent. Condemning the MRC as an ‘impla-
cable stony-faced god of numbers’, Faulder claimed that that vul-
nerable women were effectively being deceived into ‘sacriﬁc[ing]’
their children for the sake of statistical certainty (1985, p. 92).
When the MRC sought to dissuade critics of the trial from express-
ing their concerns in public, Nature ran an intentionally ‘spectacu-
lar’ blank space on the editorial pages in protest at a blatant
attempt to stiﬂe professional debate (Veitch, 1982a).13 More gener-
ally, newspapers produced a whole language around the trial distinct
from the expert discourse. ‘Study mothers’ were recast as ‘guinea
pigs’ and ‘heartbreak mums’; ‘affected pregnancies’ became ‘tragic
babes’; multivitamins counted as ‘special pills’ and placebos were
‘fake ones’ (Ferriman, 1982; King, 1982; Roxan, 1982; Toulson,
1982; Veitch, 1982b).
Second, industry had a vested interest in the design and inter-
pretation of the trial. Beecham, who supplied Smithells with the
‘blunderbuss’ multivitamin criticized by epidemiologists, with-
drew from the MRC study in 1981, unwilling either to manufacture
supplements other than Pregnavite or to provide them free of
charge (MRC ﬁle note, National Archives FD23/5152). Beecham’s
medical director had also raised concerns about the ethics of the
placebo group. The MRC took this stance as a subterfuge, recogniz-
ing Beecham’s obvious interest in having the assumed effective-
ness of ‘their mixture’ demonstrated by a major clinical trial and
the likelihood that the supplements would be ultimately recom-
mended to ‘the entire population of women at risk of becoming
pregnant’ (Davis, 1982a). Beecham’s announcement in 1982 that
it had withdrawn from the trial because ‘it believed the Smithells
work was conclusive’ coincided with the most intense phase of
the media controversy (Bryan, 1982b). Within months of the pub-
lication of the vitamin study in 1991, food manufacturers an-
nounced plans to fortify proprietary products with folic acid. The
Kellogg Company, for instance, launched a new marketing cam-
paign targeted at ‘women of childbearing age’, drawing on the
MRC study as proof that ‘babies beneﬁt from a healthy breakfast
even before they’re conceived’.14 At precisely the time advertisers
used fetal images to sell family cars (Taylor, 1992), invoking the ben-
eﬁts of folic acid to ‘babies’ even before pregnancy helped market
breakfast cereal.15 In the early 1990s, folic acid fortiﬁcation becamefor clinical research into IVF: Johnson, Franklin, Cottingham, & Hopwood (2010).
, p. 3.
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processed foods, preceding ofﬁcial public health initiatives by some
four years (Nestle, 2007, pp. 303–304).16 As of 2013, pharmaceutical
companies remain the main corporate sponsors of folic acid aware-
ness campaigns, on which they rely to promote other ‘pregnancy
vitamin’ combinations.17
Third, charities, patient advocates and consumer groups were
deeply involved in the controversy from the start, actively inﬂu-
encing the design of the trial. Most directly, the cooperation of
the Association for Spina Biﬁda and Hydrocephalus (ASBAH) was
crucial to the recruitment of research subjects. Preconditions for
ASBAH endorsement were that participants would be ‘adequately
briefed’ before giving their consent and that even the placebo
group would receive a mineral supplement containing iron and
calcium rather than a ‘dummy pill’ (Bryan, 1982a; Wynn,
1982).18 ASBAH was part of a coalition of women’s health and dis-
ability organizations campaigning for the reform of maternity care,
including the National Childbirth Trust (NCT), the Association for
the Improvement of Maternity Services, the Foundation for Educa-
tion and Research into Childbearing and the Maternity Alliance.
Although these ‘consumer’ groups differed in their objectives and
methods, by the early 1980s they came to focus much of their cam-
paigning around reducing maternal poverty and preventing handi-
cap (Oakley, 1984, pp. 236–249; Wynn & Wynn, 1979). While the
MRC won the support of ASBAH by revising the trial protocols, the
maternity groups remained critical, arguing that the study ignored
the real problem of dietary deﬁciency among socio-economically
disadvantaged women (National Childbirth Trust, 1983). The Mater-
nity Alliance, in particular, sought to highlight the wider issue of
maternal poverty, agitating against the Thatcher Government’s cuts
to the maternity budget and for the provision of free vitamins to
pregnant women (Phillips, 1984, 1986). This campaign framed
broader debate over the importance of pre-conceptional nutrition
and the prevention of disability.
Fourth, media coverage of the trial mobilized individuals and
groups sympathetic to the agendas of the overlapping anti-abortion
and disability ‘right-to-life’ movements. Pro-life groups’ opposition
to the trial built on recent campaigns against prenatal screening
and efforts to instigate criminal proceedings against medical practi-
tioners for the selective non-treatment of newborns with disabilities
(Read & Clements, 2004). The then largest ‘pro-life’ organization in
the UK, the Society for the Protection of the Unborn Child (SPUC)
led the anti-abortion response fromsummer1983, coordinatingpick-
ets of branches of Boots chemists,whosepharmaceutical division had
supplied the multivitamin and placebo pills.19 Leaﬂets handed out at
the pickets demanded the MRC ‘stop these immoral trials . . . con-
demned as immoral and repugnant bymany organizations and doctors
throughout the country’. SPUC claimed the ‘Smithells regimen’ was
‘widely recognized throughout the world’, urging the public to write
to their MPs and to ‘support spina biﬁda people’ by boycotting Boots
and complaining to their local stores.20 Although SPUC led protests
against the trial, anti-abortiongroupsconsistently framed ‘vitaminpro-
phylaxis’ as more ‘morally acceptable’ than both terminating pregnan-
cies for fetal abnormality and research on human embryos.21 Pro-life
MPs invoked this claim in parliamentary debates around the almost
successful Unborn Children (Protection) Bill in 1985 and the Human
Fertilisation and Embryology Act in 1990, reinforcing the view that16 Industry has used clinical trials more generally as a means of promoting speciﬁc prod
17 For instance, Bayer HealthCare and Vitabiotics, both manufacturers of proprietary preg
(renamed SHINE in 2011): http://www.gofolic.co.uk/, accessed 10 February 2013.
18 Women were allocated at random to one of four supplementation groups, the supplem
calcium.
19 Catholic Herald, 12 August 1983, p. 3. On SPUC, founded in 1967 to campaign for refor
20 All quotes from SPUC leaﬂet (1983).
21 Gray (1983); Catholic Herald, 18 March 1983, p. 3.
22 On the embryo research debate, see Mulkay (1997) and Theodosiou & Johnson (2010)certainty in pre-conceptional vitamin supplementation had already
been achieved (Evans & McLaren, 1985; Hansard, 1990: Winterton).22
Industry, consumer groups, and pro-life activists were all in-
vested, for different reasons, in promoting ‘better’ nutrition before
and during pregnancy. Controversy around the MRC trial drew
these heterogeneous actors, as well as research scientists, clini-
cians and journalists, into a single ‘arena of concern and action’
(Clarke, 1998, p. 16); all were heavily involved in the development
and marketing of pre-conceptional vitamin supplements. The cru-
cial role of these groups in the public construction of certainty and
uncertainty is essential for understanding the emerging identity of
folic acid as a risk-reducing drug. Their involvement both general-
ized and popularized discussions on the relationship between
nutritional deﬁciencies and NTDs, turning pre-conception vitamin
supplementation into a risk-reducing strategy not only for ‘high-
risk mothers’ but for all women planning a pregnancy. By organiz-
ing for and against the trial, moreover, the healthcare industry, the
media and patient advocates, also helped to reify the concept of
‘pre-pregnancy’ as a legitimate focus of medical and social
intervention.
Immediately following the publication of the MRC study, the UK
Chief Medical Ofﬁcer issued a circular recommending that all wo-
men of childbearing age signiﬁcantly increase their daily folate in-
take (Acheson, 1991). In the same year, the parliamentary health
committee conﬁrmed that the expansion of ‘preconception care’
would be a key objective of maternity services reform (Health
Committee, 1991). Although increasingly offered within NHS hos-
pitals by the mid-1980s, ‘pre-conception clinics’ originated as a
private healthcare initiative. Largely associated with Foresight, a
charity established in 1979 for the ‘promotion of pre-conceptual
care’, the clinics focused on preparing women for pregnancy as a
means of ‘preventing handicap’ (Oakley, 1984, p. 291). Promoted
in the media and by maternity consumer groups through the
1980s and early 1990s, Foresight has campaigned to raise aware-
ness of ‘risks to the foetus of nutritional deﬁciencies’, as well as
marketing their branded vitamin supplements, to help couples
‘build a better baby’ (Cochrane, 1983). This innovation provoked
mixed responses. Some in the medical profession saw pre-concep-
tion care as a means of helping obstetricians to ‘reduce further fetal
wastage and the incidence of malformation’ (Anon, 1981;
Smithells, 1984, p. 433); for others, it merely dragged ‘the medi-
calisation of pregnancy and birth backwards to cover conception
as well’ (Anon, 1985, p. 1047). British feminists took pre-pregnancy
care as emblematic of the ‘moral climate’ of the 1980s, coinciding
with attempts by the ‘New Right’ to reduce the legal limit of abor-
tion, and extending social expectations around the responsibilities
of motherhood to include not only pregnancy, but also the period
before conception (McNeil, 1991, p. 151). Pre-conception care has
nevertheless become an international movement, with the promo-
tion of folic acid supplementation a key objective (Casper & Moore,
2009, pp. 67–72).
6. Conclusion
Originally prescribed to pregnant women in order to reduce the
risk of anaemia, folic acid was by the late twentieth century a
technology of ‘pre-pregnancy’ for preventing neural tube defects,ucts and building brand loyalty: Petryna (2009, p. 96).
nancy vitamins, sponsor the most recent folic acid education campaign run by ASBAH
ents containing folic acid, multivitamins, both, or neither. All contained both iron and
m, and ultimately repeal, of the Abortion Act, see Marsh & Chambers (1981).
.
286 S. Al-Gailani / Studies in History and Philosophy of Biological and Biomedical Sciences 47 (2014) 278–289the most common congenital malformations. As one component of
the Pregnavite multivitamin, it was an ‘experimental drug’ for wo-
men at ‘high risk’ of bearing a child with an NTD. By the mid-1990s,
health education materials recommended folic acid supplements
to ‘all women who may bear children’. If epidemiology in the tra-
dition of social medicine encouraged NTDs to be understood in
relation to social problems of poverty and malnutrition, by the
end of the century they were more likely to be attributed to indi-
vidual women’s failure to respond appropriately to expert guid-
ance. New guidelines about preconceptional and prenatal
nutrition came as medical research and related advice concerning
pregnancy in general, including the risks maternal drinking, smok-
ing and drug taking posed to the fetus, proliferated in the 1980s
and 1990s (Daniels, 1993). At that time, a few health activists
and journalists observed that the extreme focus on expectant wo-
men’s personal accountability for birth outcomes not only served
to intensify both their anxieties during pregnancy and feelings of
guilt about bearing a disabled baby, but also distracted attention
from debate over the socioeconomic determinants of maternal
and infant health (Kent, 1986). Feminist scholars have since widely
critiqued the ‘‘privatization of risk’’ in pregnancy and the exagger-
ated emphasis on maternal responsibility for unborn or even yet-
to-be conceived fetuses that dietary guidelines have encouraged
(Lupton, 2012; Markens, Browner, & Press, 1997). But demands
for expectant women to engage in risk-aversive behaviours, this
article suggests, did not result straightforwardly from medical pro-
fessionals’ aspirations to expand the scope of obstetric control over
pregnancy.
The trajectory of folic acid from experimental drug to necessary
pre-conceptional supplement was negotiated over several decades
by the medical researchers, healthcare industry, the media, con-
sumer groups and activists. Reﬂecting on the controversy over
the MRC study in 1984, the sociologist Ann Oakley observed that
‘diet is something everyone is an expert on, and the idea that mal-
formed fetuses can be prevented by a healthy diet . . . [has] a long
history and a commonsense appeal’ (1984, p. 290). Activists’ inter-
est in nutrition, especially of mothers and infants, both followed
and supported a swathe of research across the medical and social
sciences during the 1970s and 1980s. Debates over folic acid need
to be placed more fully in relation to the wider politicization of
food and nutrition in this period (Nestle, 2007; Scrinis, 2013). Med-
ical research into folic acid was, perhaps above all, stimulated by
the emergence of spina biﬁda as a political concern in Britain
around 1970. This transformation remains poorly documented,
and we need more nuanced histories of the connections between
medical innovations, public health policies and ‘disability rights’
activism in a period of rapid change. By 1991 the context was en-
tirely different; the birth prevalence of NTDs had declined signiﬁ-
cantly and spina biﬁda was far less visible than it had been even
ten years earlier.23 The conclusion of the MRC study was neverthe-
less an important watershed in that it directly informed health pol-
icies in the UK and around the world. Yet its publication merely
opened up a new phase of controversy.
The 1996 ruling by the United States Food and Drug Adminis-
tration to implement a national folic acid fortiﬁcation policy was
widely hailed as ‘a true victory in the battle to enhance the health
of future generations of babies’ (Junod, 2001; Semba, 2006, p. 176).
Yet consumer groups and food campaigners accused the FDA of
mass-medicating the American population without thoroughly
understanding the long-term effects of folic acid consumption
and working in the interests of manufacturers of often expensive
processed foods. Similar arguments have been raised in opposition23 Epidemiologists suggest that the birth prevalence of NTDs in England andWales has dec
2004), but remain second only to cardiac anomalies as the most common congenital malfto mandatory fortiﬁcation in the United Kingdom (Blythman, 2007,
2008; Nestle, 2007, pp. 303–304; Wofﬁnden, 1998). As of 2009,
over 65 countries worldwide had followed the US lead. Numerous
scientiﬁc advisory bodies have recommended mandatory folic acid
fortiﬁcation to successive UK governments, but experts remain
locked in debate over the risks and beneﬁts (Wald & Oakley,
2007). Advocates of fortiﬁcation have consistently complained
that, because more than half of all pregnancies are unplanned,
the educational campaigns hitherto favoured in the UK and other
European countries are inadequate (Smith, Davies, & Davies,
1994; Sutcliffe, Schorah, Perry, & Wild, 1993). Opponents have ar-
gued that high folic acid intake may both mask the signs of anae-
mia in diets deﬁcient in vitamin B12 and accelerate the
development of certain cancers (Hubner, Houlston, & Muir,
2007). Scientiﬁc disagreement, in addition to perceived govern-
mental recalcitrance, has made folic acid enormously contentious
in Britain over the last two decades.
The tumultuous trajectory of pre-conceptional folic acid supple-
mentation invites comparisons with other postwar medical inter-
ventions, particularly those concerned with reducing the risk of
congenital and genetic disability and disease. Further research
might also ask to what extent measures to encourage ‘pre-preg-
nant’ women to consume supplements have followed precedents
set by rubella vaccination (Reagan, 2010), newborn screening for
phenylketonuria (Lindee, 2005; Paul, 1998, pp. 173–186) and cam-
paigns around smoking in pregnancy (Berridge & Loughlin, 2008)
and fetal alcohol syndrome (Armstrong, 2003; Golden, 2005). Like
prenatal diagnosis, these innovations have contributed to the inex-
orable rise of the fetus in medical practice and public debate.
Continuing disagreement among health policy makers over folic
acid also open up further questions about varied public responses
and assessments of success or failure in different national contexts.
In particular, the ways in which the fate of pre-conceptional vita-
min supplementation was tied to other modalities of reducing
birth defects—speciﬁcally, prenatal testing and selective termina-
tion—and controversies around them demand further study. Like
many recent public health innovations, folic acid was scaled up
from an individual treatment for selected, high-risk individuals
into a means of accomplishing population health goals. As public
health experts continue to debate the risks and beneﬁts, it none-
theless remains an experiment-in-progress.
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